Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma

Area of Science:

• Immunology
• Metabolism
• Oncology

Background:

• The kynurenine pathway (KP) influences cancer immunity, primarily through indoleamine 2,3-dioxygenase 1 (IDO1).
• The roles of other KP metabolites, like 3-hydroxy kynurenine (3-HK) and kynurenic acid (KYNA), in modulating the tumor microenvironment are not well understood.
• Understanding KP metabolite interactions with T-cells is crucial for developing effective cancer immunotherapies.

Purpose of the Study:

• To investigate the association between the kynurenine metabolic pathway and CD4+ T-cell status in cutaneous melanoma.
• To characterize the production of kynurenine (KYN), 3-HK, and KYNA in response to T-cell activation.
• To identify novel immune regulatory mechanisms within the tumor microenvironment.

Main Methods:

• Analysis of gene expression data from 368 cutaneous melanoma (SKCM) patients (TCGA cohort).
• In vitro characterization of KYN, 3-HK, and KYNA production in melanoma cell lines and primary CD4+ T-cells.
• Correlation network analysis of TCGA-SKCM data, focusing on KMO and KYNU expression variability.

Main Results:

• Activated CD4+ T-cells produced IFNγ, increasing KYN and KYNA levels.
• Increased KP metabolite production correlated with reduced CD4+ T-cell proliferation and increased exhaustion markers (PD-L1, AHR, FOXP3, CTLA4).
• Lower kynurenine 3-monooxygenase (KMO) expression and higher KYNA production were linked to dysfunctional effector CD4+ T-cell responses, particularly in BRAF wild-type melanoma.

Conclusions:

• The kynurenine pathway, beyond IDO1, involves alternative immune regulatory mechanisms.
• Lower KMO expression and higher KYNA production contribute to impaired effector CD4+ T-cell function in melanoma.
• Targeting KMO and KYNA may offer novel strategies for enhancing anti-tumor immunity.